FDA Mulls Label Changes for Some Osteoporosis Drugs; FDA Advises Doctors: Be Aware of Unusual Femur Fractures
BOSTON, Sept 14 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it may require a class of osteoporosis drugs known as bisphosphonates to carry new information related to unusual femur fractures.